Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging geography in the heart, for delivering electric signals that more closely ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...

The OmniaSecure lead gained the first U.S. approval for placement in the heart’s left bundle branch area, to help activate the natural electrical system.

A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...

The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.

Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.

Medtronic snagged FDA approval for an expanded indication for its OmniaSecure defibrillation lead. Check out why this tiny lead packs a big punch.

Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for left bundle branch block in heart failure.

Physiologic pacing of the His-Purkinje conduction system is feasible in patients who require a permanent pacemaker following TAVR and this alternative pacing method did not interfere with ejection ...

Please provide your email address to receive an email when new articles are posted on . Left bundle branch pacing was achieved for the first time via leadless pacemaker. Implantation failure rate was ...

Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...